Regenerative Potent ial of Adipose-Derived Mesenchymal Stem Cells in The Treatment of Type 1 And Type 2 Diabetes Mellitus (Review)

The article is devoted to the analysis of the therapeutic potential of mesenchymal stem cells obtained from adipose tissue in the treatment of diabetes mellitus types 1 and 2 and their complications. Brief information on the prevalence of the disease is provided, the main existing approaches to the treatment of diabetes mellitus aimed at maintaining normal glucose and glycated hemoglobin levels are considered, the use of mesenchymal stem cells obtained from adipose tissue is based. The main disadvantage of insulin therapy is the impossibility of imitation the physiological regulation of the glycemic profile and completely eliminating vascular complications in patients. This fact became the reason for searching for more advanced techniques using the regenerative potential of mesenchymal stem cells obtained from adipose tissue. The morphological and immunohistochemical features of these cells are described; a wide range of growth factors and signaling molecules determining their immunomodulatory, antioxidant and antiapoptotic properties is characterized. The paracrine effect of mesenchymal stem cells obtained from adipose tissue can be used in transplantation of pancreatic islets to increase their survival. The ability to preserve the residual mass of the patient’s β-cells, as well as to supply their number by differentiating into insulin-producing cells determines the use of these cells in the treatment of type 1 diabetes mellitus. At the same time, a positive effect on the mechanisms of insulin resistance, stimulation of glycogenesis and regulation of the glycemic profile characterizes the demand for them in the treatment of type 2 diabetes mellitus. Pluripotency and plasticity of mesenchymal stem cells obtained from adipose tissue allow their use in the treatment of diabetic complications: trophic ulcers, diabetic retinopathy and nephropathy. The state of clinical trials aimed at obtaining evidence-based data on the efficacy and safety of mesenchymal stem cells obtained from adipose tissue in the treatment of types 1 and 2 diabetes mellitus is discussed.

1. Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104-123. doi: 10.14341/DM13035 [in Russian].

2. Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. doi: 10.14341/DM12759 [in Russian].

3. Анорбоев Ж.А., Умиров Ш.Т., Салайдинов О.Р. и др. Сахарный диабет: эпидемия столетия. Science and Education. 2023;.4(5):555-564. Anorboev Zh.A., Umirov Sh.T., Salaidinov O.R. et al. Diabetes mellitus: the epidemic of the century. Science and Education. 2023;.4(5):555-564 [in Russian].

4. Zhdanova E.A., Volynkina A.P., Kolimbet L.P.et al. Clinical and epidemiological characteristics of diabetes mellitus and its complications in the Voronezh region. Russian Medical Journal. 2023;7(9):560-565. doi: 10.32364/2587-6821-2023-7-9-1 [in Russian].

5. Classification of diabetes mellitus. World Health Organization, 2019. [Electronic resource]. URL: https://apps.who.int/iris/handle/10665/325182 (date of the application: 22.01.2026).

6. Bulgakova S.V., Dolgikh Yu.A., Sharonova L.A. et al. The evolution of type 1 diabetes treatment. Endocrinology: news, opinions, training. 2023;12(3):46-53. doi: 10.33029/2304-9529-2023-12-3-46-53 [in Russian].

7. Kuzhekina Yu.S., Vorobyeva A.S., Vasilenko S.A.et al. Achievements of genetic engineering in the treatment of diabetes mellitus. International Student Scientific Bulletin. 2017;(6):164 [in Russian].

8. Pylaev T.E., Smyshlyaeva I.V., Popyhova E.B. Regeneration of β-cells of the islet apparatus of the pancreas. Literature review. Diabetes mellitus. 2022;25(4):395-404. doi: 10.14341/DM12872 [in Russian]

9. Huang Y, Wang Y, Liu C et al. C-peptide, glycaemic control, and diabetic complications in type 2 diabetes mellitus: A real-world study. Diabetes Metab Res Rev. 2022;38(4):e3514. doi: 10.1002/dmrr.3514.

10. Shapiro A.M., Ricordi C., Hering B.J. et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318-30. doi: 10.1056/NEJMoa061267.

11. Chetboun M., Drumez E., Ballou C. et al. Collaborative Islet Transplant Registry (CITR) Investigators study group. Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry. Lancet Diabetes Endocrinol. 2023;11(6):391-401. doi: 10.1016/S2213-8587(23)00082-7.

12. Langlois A., Pinget M., Kessler L.et al. Islet Transplantation: Current Limitations and Challenges for Successful Outcomes. Cells. 2024;13(21):1783. doi: 10.3390/cells13211783.

13. Mikhliev Sh.Sh., Safarav A.U., Aminov A.Kh. et al. Diabetes mellitus. Science and Education. 2023;4(5):544-554 [in Russian]

14. Zhou Y., Zhang X.L., Lu S.T. et al. Human adipose-derived mesenchymal stem cells-derived exosomes encapsulated in pluronic F127 hydrogel promote wound healing and regeneration. Stem Cell Res Ther. 2022;13(1):407. doi: 10.1186/s13287-022-02980-3.

15. Mikłosz A., Chabowski A. Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus. J Clin Endocrinol Metab. 2023;108(8):1889-1897. doi: 10.1210/clinem/dgad142.

16. Mazini L., Rochette L., Admou B. et al. Hopes and Limits of AdiposeDerived Stem Cells (ADSCs) and Mesenchymal Stem Cells (MSCs) in Wound Healing. Int J Mol Sci. 2020;21(4):1306. doi: 10.3390/ijms21041306.

17. Karakursakov N.E., Aramyan E.E., Zinchenko M.S. et al. The use of insulin-producing cells in the treatment of type 1 diabetes mellitus. The Tauride Medical and Biological Bulletin. 2022;28(2):178-186 [in Russian].

18. Badr O.I., Kamal M.M., El-Maraghy S.A. et al. The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulinproducing cells. Biol Res. 2024;57(1):20. doi: 10.1186/s40659-024-00502-4.

19. Yan D., Song Y., Zhang B. et al. Progress and application of adiposederived stem cells in the treatment of diabetes and its complications. Stem Cell Res Ther. 2024;15(1):3. doi: 10.1186/s13287-023-03620-0.

20. Lykov A.P. Mesenchymal stem cells: properties and clinical application. Siberian Scientific Medical Journal. 2023;43(2):40-53 [in Russian].

21. Jiao Y.R., Chen K.X., Tang X et al. Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications. Cell Death Dis. 2024;15(4):271. doi: 10.1038/s41419-024-06659-w.

22. Ahmadieh-Yazdi A., Karimi M., Afkhami E. et al.. Unveiling therapeutic potential: Adipose tissue-derived mesenchymal stem cells and their exosomes in the management of diabetes mellitus, wound healing, and chronic ulcers. BiochemPharmacol. 2024;226:116399. doi: 10.1016/j.bcp.2024.116399.

23. Wang X., Chen S., Lu R. et al. Adipose-derived stem cell-secreted exosomes enhance angiogenesis by promoting macrophage M2 polarization in type 2 diabetic mice with limb ischemia via the JAK/STAT6 pathway. Heliyon. 2022;8(11):e11495. doi: 10.1016/j.heliyon.2022.e11495.

24. Lan T., Luo M., Wei X. Mesenchymal stem/stromal cells in cancer therapy. J Hematol Oncol. 2021;14(1):195. doi: 10.1186/s13045-021-01208-w.

25. Yang Y.M., Dong X.H., Ma W.C. et al. Proliferation, Differentiation and Immunoregulatory Capacities of Brown and White AdiposeDerived Stem Cells from Young and Aged Mice. Int J Stem Cells. 2020;13(2):246-256. doi: 10.15283/ijsc20019.

26. Xiong J., Hu H., Guo R. et al. Mesenchymal Stem Cell Exosomes as a New Strategy for the Treatment of Diabetes Complications. Front Endocrinol (Lausanne). 2021;12:646233. doi: 10.3389/fendo.2021.646233.

27. Araujo D.B., Dantas J.R., Silva K.R. et al. Allogenic Adipose TissueDerived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study. Front Immunol. 2020;11:993. doi: 10.3389/fimmu.2020.00993.

28. Dai P., Qi G., Xu H. et al. Reprogramming adipose mesenchymal stem cells into islet в-cells for the treatment of canine diabetes mellitus. Stem Cell Res Ther. 2022;13(1):370. doi: 10.1186/s13287-022-03020-w.

29. Sylow L., Tokarz V.L., Richter E.A. et al. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 2021;33(4):758-780. doi: 10.1016/j.cmet.2021.03.020.

30. Gao Z., Zhang X., Zuberi A. et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol. 2004;18(8):2024-34. doi: 10.1210/me.

31. Dong Z., Fu Y., Cai Z. et al. Recent advances in adipose-derived mesenchymal stem cell-derived exosomes for regulating macrophage polarization. Front Immunol. 2025;16:1525466. doi: 10.3389/fimmu.2025.1525466.

32. Wang L.X., Zhang S.X., Wu H.J. et al. M2b macrophage polarization and its roles in diseases. J Leukoc Biol. 2019;106(2):345-358. doi: 10.1002/JLB.3RU1018-378RR.

33. Gamble A., Pawlick R., Pepper A.R. et al. Improved islet recovery and efficacy through co-culture and co-transplantation of islets with human adipose-derived mesenchymal stem cells. PLoS One. 2018;13(11):e0206449. doi: 10.1371/journal.pone.0206449.

34. Dantas J.R., Araújo D.B., Silva K.R. et al. Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients. Arch Endocrinol Metab. 2021;65(3):342-351. doi: 10.20945/2359-3997000000368.

35. Dantas J.R., Araujo D.B., Silva K.R. et al. Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up. Horm Metab Res. 2023;55(8):536-545. doi: 10.1055/a-2094-1039.

36. Hu J., Fu Z., Chen Y. et al. Effects of autologous adipose-derived stem cell infusion on type 2 diabetic rats. Endocr J. 2015;62(4):339-52. doi: 10.1507/endocrj.EJ14-0584.

37. Boushra A.F., Mahmoud R.H., Ayoub S.E. et al. The Potential Therapeutic Effect of Orexin-Treated versus Orexin-Untreated Adipose Tissue-Derived Mesenchymal Stem Cell Therapy on Insulin Resistance in Type 2 Diabetic Rats. J Diabetes Res. 2022;2022:9832212. doi: 10.1155/2022/9832212.

38. Nam J.S., Kang H.M., Kim J. et al. Transplantation of insulin-secreting cells differentiated from human adipose tissue-derived stem cells into type 2 diabetes mice. BiochemBiophys Res Commun. 2014;443(2):775-781. 10.1016/j.bbrc.2013.10.059.

39. Woo S.H., Choi J.H., Mo Y.J. et al. Engineered elastin-like polypeptide improves the efficiency of adipose-derived stem cell-mediated cutaneous wound healing in type II diabetes mellitus. Heliyon. 2023;9(9):e20201. doi: 10.1016/j.heliyon.2023.e20201.

40. Quiñones E.D., Wang M.H., Liu K.T. et al. Extracellular vesicles from human adipose-derived stem cell spheroids: Characterization and therapeutic implications in diabetic wound healing. Mater Today Bio. 2024;29:101333. doi: 10.1016/j.mtbio.2024.101333.

41. Bour F., Khalilollah S., Omraninava M.et al. Three-dimensional bioengineered dermal derived matrix scaffold in combination with adipose-derived stem cells accelerate diabetic wound healing. Tissue Cell. 2024;87:102302. doi: 10.1016/j.tice.2024.102302.

42. Ma T., Zhao Y., Shen G. et al. Novel bilayer cell patch combining epidermal stem cells and angiogenic adipose stem cells for diabetic wound healing. J Control Release. 2023;359:315-325. doi: 10.1016/j.jconrel.2023.06.010.

43. Zheng J., Wang R., Wang Y. New concepts drive the development of delivery tools for sustainable treatment of diabetic complications. Biomed Pharmacother. 2024;171:116206. doi: 10.1016/j.biopha.2024.116206.

44. Abd El-Lateef H.M., Qahl S.H., Fayad E. et al. The potency of N, N̕-diphenyl-1,4-phenylenediamine and adipose-derived stem cell co-administration in alleviating hepatorenal dysfunction complications associated with type 1 diabetes mellitus in rats. Biocell. 2023;47(8):1885-1895. doi: 10.32604/biocell.2023.030680.

45. Malagutti-Ferreira M.J., Crispim B.A., Barufatti A. et al. Genomic instability in long-term culture of human adipose-derived mesenchymal stromal cells. Braz J Med Biol Res. 2023;56:e12713. doi: 10.1590/1414-431X2023e12713.

46. Zhang Y., Wang C., Li J.J. Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression. Exp Hematol Oncol. 2024;13(1):64. doi: 10.1186/s40164-024-00532-4.

47. Kim J.S., Lee J.H., Kwon O.et al. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy. Kidney Res Clin Pract. 2017;36(2):200-204. doi: 10.23876/j.krcp.2017.36.2.200.

48. Centeno C.J., Al-Sayegh H., Freeman M.D. et al. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop. 2016;40(8):1755-1765. doi: 10.1007/s00264-016-3162-y.

49. Olmedo-Moreno L, Aguilera Y, Baliña-Sánchez C. et al. Heterogeneity of In Vitro Expanded Mesenchymal Stromal Cells and Strategies to Improve Their Therapeutic Actions. Pharmaceutics. 2022;14(5):1112. doi: 10.3390/pharmaceutics14051112.

50. Baranovskii D.S., Klabukov I.D., Arguchinskaya N.V. et al. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investig. 2022;9:7. doi: 10.21037/sci-2022-025.